A phase 1/2 trial of CM350 group1 in advanced solid tumours, run by Keymed Biosciences Co.Ltd, now recruiting.
A Study of CM350 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05263960 by Keymed Biosciences Co.Ltd, with 248 participants planned, started 2022-04-21 and due to reach its primary completion in 2027-04. Interventions recorded: CM350 group1, CM350 group2 and CM350 group3.
Shares Keymed Biosciences (KYM Biosciences), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Keymed Biosciences (KYM Biosciences) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.